ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results
03 août 2023 08h09 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company” or “ProSomnus”) (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”),...
ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation
13 juil. 2023 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced plans to design a...
ProSomnus Announces Second Quarter 2023 Investor Call and Business Update
06 juil. 2023 08h29 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its strong second...
71% of Self-identified Snorers Have Never Consulted a Healthcare Professional
28 juin 2023 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), announced the results of a...
Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea
08 juin 2023 16h08 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced the presentation of...
Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea
30 mai 2023 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced the...
ProSomnus Reports First Quarter 2023 Financial Results
09 mai 2023 16h00 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company” or “ProSomnus”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea...
ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences
26 avr. 2023 09h00 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), will...
Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances
24 avr. 2023 16h05 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...
ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting
18 avr. 2023 08h00 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...